To the Editor: The report by Dr. Tamborlane and his colleagues1 confirmed our preliminary results2 3 4 on short-term, continuous, subcutaneous insulin infusion (CSII) in insulin-dependent diabetics. The portable Auto Syringe that they used clearly has a more flexible rate adjustment than our earlier model had, but this versatility can only be bought at a price that we considered excessive. The drawbacks are the weight and bulk of the device and, of equal importance, the liability to ill advised tinkering and tampering with infusion rates. Simplicity and reliability seem to us to be primary requirements. In view of the current surge of.
ASJC Scopus subject areas